About the Renmab™ Platform
RenMab™ is designed to eliminate current bottlenecks faced during therapeutic antibody discovery. We envision it to be a leading platform that challenges the status quo and offers maximum potential to fill the unmet needs in discovering different antibody types and targets.
RenMab is an innovative technology of Biocytogen.
The RenMab™ platform is an innovation resulting from the interdisciplinary collaboration between geneticists and immunologists within Biocytogen. Our scientific teams realized the current shortcomings in antibody discovery using transgenic animals in the current market landscape. As a result, the teams came together and worked hard to craft a better solution that will push the boundary of biomedical science.
Despite a handful of transgenic mouse models available for human antibody generation, many of these models are based on old genetic editing technologies, which limits the complete replacement of murine antibody genes, resulting in the incomplete human antibody repertoire and often lower performance. With the focus on translational success, Biocytogen utilized chromosome engineering to generate the RenMab™ Mouse, which can produce human-like antibodies with excellent diversity and affinity. The robust and fully validated RenMab™ platform is poised to become a powerhouse in antibody discovery innovation.
Biocytogen provides one-stop solutions for next-generation drug development, from target to IND application to the global biomedical communities. Empowered by its cutting-edge gene editing technologies and state-of-art animal facility, Biocytogen developed a seamlessly integrated platform for efficient antibody drug discovery.
The technical teams in Biocytogen support a comprehensive portfolio of products and services, covering in vivo/in vitro preclinical services, animal model generation, fully human antibody (via RenMab™ Mice), therapeutic antibody discovery and development services, CMC/CDMO, and regulatory affairs support. Biocytogen collaborates with more than 70% of top 50 pharmaceutical and numerous biotech start-up companies worldwide. Together, we discover innovative medicines for a better, healthier world.
- Advance life sciences with high-quality and customized models to push the boundary of utilization of humanized target models in biomedical research
- Develop technological platforms to significantly shorten the next-generation drug discovery and development process
- Empower scientists in drug discovery by providing the necessary expertise to remove bottlenecks in research
- Be a global leader in all-around preclinical services